Predicting Anti-Cancer Drug Response Based on Hypergraph Representation Learning
Abstract:
Accurate prediction of drug responses is critical for advancing personalized cancer therapies. Although current graph neural network (GNN)-based approaches predominantly focus on pairwise interactions between cell lines and drugs, they often neglect the potential of higher-order interactions. In this study, we present HRLCDR, a novel computational framework that utilizes Hypergraph Representation Learning to predict Cancer Drug Responses. HRLCDR begins by constructing hypergraphs for both cell lines and drugs and then processes through low-pass and high-pass hypergraph convolutions, allowing the model to extract both common and different features from the complex higher-order interactions between cell lines and drugs. After that, HRLCDR constructs a heterogeneous graph using known cell line responses to drugs. Parallel heterogeneous graph convolution operations are then employed to extract primary interaction features between cell lines and drugs from these associations. Finally, HRLCDR integrates the features learned from both the hypergraphs and the heterogeneous graph, predicting drug response via Classifiers. We evaluated HRLCDR's performance on two major cancer drug response datasets: the Cancer Drug Sensitivity Data (GDSC) and the Cancer Cell Line Encyclopedia (CCLE). The results demonstrate that HRLCDR outperforms current state-of-the-art methods, underscoring its potential to enhance the accuracy and reliability of cancer drug response predictions.
Insights
This study introduces HRLCDR, a new computational framework for predicting cancer drug responses by analyzing higher-order interactions. HRLCDR improves upon existing methods, offering more accurate predictions for personalized cancer therapies.
Area of Science:
- Computational biology
- Bioinformatics
- Machine learning in oncology
Background:
- Personalized cancer therapy relies on accurate drug response prediction.
- Current graph neural network (GNN) methods often overlook complex, higher-order interactions between cell lines and drugs.
- There is a need for advanced computational frameworks to capture these intricate relationships.
Purpose of the Study:
- To develop and evaluate HRLCDR, a novel Hypergraph Representation Learning framework for predicting cancer drug responses.
- To leverage higher-order interactions for improved prediction accuracy.
- To enhance the reliability of computational models in precision oncology.
Main Methods:
- Constructing cell line and drug hypergraphs and applying hypergraph convolutions to extract features.
- Building a heterogeneous graph from known cell line-drug responses and employing graph convolutions.
- Integrating features from hypergraph and heterogeneous graph analyses for drug response prediction using classifiers.
Main Results:
- HRLCDR effectively extracts common and distinct features from higher-order interactions.
- The framework demonstrates superior performance compared to state-of-the-art methods on GDSC and CCLE datasets.
- HRLCDR shows significant potential in enhancing the accuracy of cancer drug response predictions.
Conclusions:
- HRLCDR offers a powerful approach to model complex interactions for drug response prediction.
- The framework advances the field of computational oncology and personalized medicine.
- HRLCDR's ability to capture higher-order interactions is key to its improved predictive performance.
Related Concept Videos
01:21Cancer Survival Analysis
02:26Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...